BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33433118)

  • 1. Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance.
    Park Y; Lee JH; Sinn DH; Park JY; Kim MA; Kim YJ; Yoon JH; Kim DY; Ahn SH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Clin Transl Gastroenterol; 2021 Jan; 12(1):e00290. PubMed ID: 33433118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.
    Kim GA; Lee HC; Kim MJ; Ha Y; Park EJ; An J; Lee D; Shim JH; Kim KM; Lim YS
    J Hepatol; 2015 May; 62(5):1092-9. PubMed ID: 25445399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
    Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
    Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    Yip TC; Chan HL; Wong VW; Tse YK; Lam KL; Wong GL
    J Hepatol; 2017 Nov; 67(5):902-908. PubMed ID: 28652084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    Yang H; Bae SH; Nam H; Lee HL; Lee SW; Yoo SH; Song MJ; Kwon JH; Nam SW; Choi JY; Yoon SK; Jang JW
    J Hepatol; 2022 Sep; 77(3):632-641. PubMed ID: 35398462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.
    Yuen MF; Wong DK; Sablon E; Tse E; Ng IO; Yuan HJ; Siu CW; Sander TJ; Bourne EJ; Hall JG; Condreay LD; Lai CL
    Hepatology; 2004 Jun; 39(6):1694-701. PubMed ID: 15185311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    Kuang XJ; Jia RR; Huo RR; Yu JJ; Wang JJ; Xiang BD; Li LQ; Peng Z; Zhong JH
    J Viral Hepat; 2018 Sep; 25(9):1026-1037. PubMed ID: 29624821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance.
    Lee HW; Lee JI; Kim S; Kim S; Chang HY; Lee KS
    BMC Gastroenterol; 2020 Apr; 20(1):113. PubMed ID: 32305059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance.
    Liu F; Wang XW; Chen L; Hu P; Ren H; Hu HD
    Aliment Pharmacol Ther; 2016 Jun; 43(12):1253-61. PubMed ID: 27117732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance.
    Choi J; Yoo S; Lim YS
    Hepatology; 2021 Jun; 73(6):2155-2166. PubMed ID: 33131063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
    J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAMP-B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance.
    Lee HW; Yip TC; Wong VW; Lim YS; Chan HL; Ahn SH; Wong GL; Choi J
    Aliment Pharmacol Ther; 2024 May; 59(10):1223-1235. PubMed ID: 38425096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B.
    Li J; Yang HI; Yeh ML; Le MH; Le AK; Yeo YH; Dai CY; Barnett S; Zhang JQ; Huang JF; Trinh HN; Wong C; Wong C; Hoang JK; Cheung R; Yu ML; Nguyen MH
    J Infect Dis; 2021 Jul; 224(2):294-302. PubMed ID: 33249474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
    Yip TC; Wong VW; Lai MS; Lai JC; Hui VW; Liang LY; Tse YK; Chan HL; Wong GL
    J Hepatol; 2023 Mar; 78(3):524-533. PubMed ID: 36463985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma.
    Chu CM
    J Gastroenterol Hepatol; 2000 May; 15 Suppl():E25-30. PubMed ID: 10921378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection.
    Chen YC; Sheen IS; Chu CM; Liaw YF
    Gastroenterology; 2002 Oct; 123(4):1084-9. PubMed ID: 12360470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.
    Yuen MF; Wong DK; Fung J; Ip P; But D; Hung I; Lau K; Yuen JC; Lai CL
    Gastroenterology; 2008 Oct; 135(4):1192-9. PubMed ID: 18722377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss.
    Yip TC; Wong VW; Tse YK; Liang LY; Hui VW; Zhang X; Li GL; Lui GC; Chan HL; Wong GL
    Aliment Pharmacol Ther; 2021 Jan; 53(2):321-331. PubMed ID: 33222272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis.
    Kim BS; Seo YS; Kim YS; Lee CH; Lee HA; Um SH; Yoo JJ; Kim SG; Suh SJ; Jung YK; Ahn SH; Han KH; Yim HJ; Kim SU;
    J Gastroenterol Hepatol; 2018 Feb; 33(2):503-510. PubMed ID: 28666070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.